MEGF0444A + bevacizumab + paclitaxel

MEGF0444A + bevacizumab + paclitaxel is an investigational combination therapy evaluated primarily for advanced or recurrent non-squamous non-small cell lung cancer (NSCLC). MEGF0444A is a monoclonal antibody targeting EGFL7, an extracellular matrix protein implicated in vascular development and tumor angiogenesis. Bevacizumab is a humanized monoclonal antibody targeting vascular endothelial growth factor A (VEGFA), inhibiting angiogenesis and tumor blood supply. Paclitaxel is a microtubule-stabilizing chemotherapeutic agent that prevents cell division. The combination aims to enhance anti-tumor efficacy via dual angiogenesis inhibition and cytotoxic chemotherapy[4][5].